

1 29. (Amended) A biologically active, dimerized
2 polypeptide fusion, comprising:

3 first and second polypeptide chains, wherein each
4 of said polypeptide chains comprises a non-immunoglobulin
5 polypeptide requiring dimerization for biological activity joined
6 to a dimerizing protein heterologous to said non-immunoglobulin
7 polypeptide.

1 30. (Amended), The biologically active, dimerized
2 polypeptide fusion of claim 29 which is a homodimer.

1 31. (Amended) The biologically active, dimerized
2 polypeptide fusion of claim 29 wherein the dimerizing protein of
3 one of said polypeptide chains comprises an immunoglobulin heavy
4 chain constant region.

1 32. (Amended) The biologically active, dimerized
2 polypeptide fusion of claim 31 wherein the immunoglobulin heavy
3 chain constant region is joined to an immunoglobulin hinge
4 region.

1 33. (Amended) The biologically active, dimerized
2 polypeptide fusion of claim 31 wherein the immunoglobulin heavy
3 chain constant region is joined to an immunoglobulin variable
4 region.

1 34. (Amended) The biologically active, dimerized
2 polypeptide fusion of claim 33 wherein the immunoglobulin
3 variable region is selected from the group consisting of V_H, V_K,
4 and V_λ.

1 35. (Amended) The biologically active, dimerized
2 polypeptide fusion of claim 29 wherein the dimerizing protein one

Andrzej Z. Sledziewski
Serial No. 08/980,400
Page 3

of said polypeptide chains comprises an immunoglobulin heavy chain constant region domain selected from the group consisting of C_H1, C_H2, C_H3, and C_H4 of a γ , α , ϵ , μ , or δ class immunoglobulin heavy chain.

36. (Amended) The biologically active, dimerized polypeptide fusion of claim 29 wherein the dimerizing protein of one of said polypeptide chains comprises an immunoglobulin light chain constant region.

37. (Amended) A biologically active, multimerized polypeptide fusion, comprising:

a non-immunoglobulin polypeptide requiring multimerization for biological activity joined to an immunoglobulin light chain constant region; and

an immunoglobulin heavy chain constant region domain selected from the group consisting of C_H1, C_H2, C_H3, and C_H4.

38. (Amended) The biologically active, multimerized polypeptide fusion of claim 37 which is a tetramer comprising four polypeptide fusions each having a non-immunoglobulin polypeptide joined to a multimerizing protein.

39. (Amended) [The] A biologically active, multimerized polypeptide fusion [of claim 37 wherein the multimerizing protein comprises] comprising: a non-immunoglobulin polypeptide requiring multimerization for biological activity joined to an immunoglobulin ^{heavy}_{light} chain constant region; and an immunoglobulin ^{heavy}_{light} chain.

40. (Amended) The biologically active, multimerized polypeptide fusion of claim 39 wherein the

(H.D.)

Andrzej Z. Sledziewski
Serial No. 08/980,400
Page 4

3 immunoglobulin heavy chain constant region is joined to an
4 immunoglobulin hinge region.

1 41. (Amended) The biologically active,
2 multimerized polypeptide fusion of claim 39 wherein the
3 immunoglobulin heavy chain constant region is joined to an
4 immunoglobulin variable region.

1 42. (Amended) The biologically active,
2 multimerized polypeptide fusion of claim 41 wherein the
3 immunoglobulin variable region is selected from the group
4 consisting of V_H, V_K, and V_λ.

1 43. (Amended) The biologically active,
2 multimerized polypeptide fusion of claim 37 [wherein the]
3 including a multimerizing protein which comprises an
4 immunoglobulin heavy chain constant region domain selected from
5 the group consisting of C_{H1}, C_{H2}, C_{H3}, and C_{H4} of a γ, α, ε, μ, or
6 δ class immunoglobulin heavy chain.

1 45. (Amended) The biologically active,
2 heteromultimeric polypeptide fusion, comprising:
3 a first polypeptide fusion comprising a first non-

4 immunoglobulin polypeptide joined to a first multimerizing
5 protein heterologous to said first non-immunoglobulin polypeptide
6 and a second polypeptide fusion comprising a second non-
7 immunoglobulin polypeptide joined to a second multimerizing
8 protein heterologous to said second non-immunoglobulin
9 polypeptide.

1 46. (Amended) The biologically active,
2 heteromultimeric polypeptide fusion of claim 45 wherein the first
3 and second non-immunoglobulin polypeptides each comprise an amino

143

Andrzej Z. Sledziewski
Serial No. 08/980,400
Page 5

acid sequence selected from the group consisting of (A) the amino acid sequence [of Figures 1A-1D (Sequence ID Numbers 1 and 2)] Sequence ID NO:2, and (B) the amino acid sequence of [Figures 11A-11D (Sequence ID Numbers 35 and 36)] Sequence ID NO:36.

17. (Amended) The biologically active,
heteromultimeric polypeptide fusion of claim 45 wherein the first
multimerizing protein is different from the second multimerizing
protein.

18. (Amended) The biologically active,
heteromultimeric polypeptide fusion of claim 47 wherein the first
and second non-immunoglobulin polypeptides are the same.

19. (Amended) The biologically active,
heteromultimeric polypeptide fusion of claim 45 wherein the first
and second multimerizing proteins each comprise an immunoglobulin
heavy chain constant region or an immunoglobulin light chain
constant region.

20. (Amended) The biologically active,
heteromultimeric polypeptide fusion of claim 45 which comprises a
first polypeptide fusion having a first non-immunoglobulin
polypeptide joined to a first immunoglobulin constant region and
a second polypeptide fusion having a second non-immunoglobulin
polypeptide fused to a second immunoglobulin constant region
different from the first immunoglobulin constant region.

21. (Amended) The biologically active,
heteromultimeric polypeptide fusion of claim 50 wherein the first
multimerizing protein comprises an immunoglobulin heavy chain
constant region and the second multimerizing protein comprises an
immunoglobulin light chain constant region.

143

1 52. (Amended) The biologically active,
2 heteromultimeric polypeptide fusion of claim 49 wherein one of
3 said multimerizing proteins comprises an immunoglobulin heavy
4 chain constant region joined to an immunoglobulin hinge region.

1 53. (Amended) The biologically active,
2 heteromultimeric polypeptide fusion of claim 49 wherein one of
3 said multimerizing proteins comprises an immunoglobulin heavy
4 chain constant region joined to an immunoglobulin variable
5 region.

1 54. (Amended) The biologically active,
2 heteromultimeric polypeptide fusion of claim 53 wherein the
3 immunoglobulin variable region is selected from the group
4 consisting of V_H , V_K , and V_λ .

1 55. (Amended) The biologically active,
2 heteromultimeric polypeptide fusion of claim 45 wherein one of
3 said multimerizing proteins comprises an immunoglobulin heavy
4 chain constant region domain selected from the group consisting
5 of C_{H1} , C_{H2} , C_{H3} , and C_{H4} of a γ , α , ϵ , μ , or δ class
6 immunoglobulin heavy chain.

1 56. (Amended) The biologically active,
2 heteromultimeric polypeptide fusion of claim 45 wherein said
3 multimerized polypeptide fusion comprises a first polypeptide
4 fusion comprising a first receptor or receptor domain requiring
5 multimerization for activity joined to a first immunoglobulin
6 constant region and a second polypeptide fusion comprising a
7 second receptor or receptor domain requiring multimerization for
8 activity joined to a second immunoglobulin constant region.

1445